IHC - CD45/LCA

IHC – CD45/LCA Test

The IHC CD45/LCA Test is a specialized immunohistochemistry (IHC) diagnostic test used to detect CD45 (Leukocyte Common Antigen - LCA) protein expression in tissue samples. CD45 is a pan-leukocyte marker present on most white blood cells, making it one of the most important biomarkers in diagnosing and classifying lymphomas, leukemias, and other hematologic malignancies.

This test plays a crucial role in hematopathology, helping pathologists determine whether abnormal tumor cells are of hematopoietic (blood cell) origin. It is especially useful for differentiating lymphoid cancers from non-hematologic tumors such as carcinomas, sarcomas, and melanomas.

The IHC CD45/LCA test is commonly used in evaluating:

• Non-Hodgkin lymphoma
• Hodgkin lymphoma (selected cases)
• Leukemia involving tissue sites
• Lymphoblastic lymphoma
• Differential diagnosis of poorly differentiated tumors

The test is performed on FFPE (Formalin-Fixed Paraffin-Embedded) tissue biopsy samples using advanced antibody staining methods. Expert hematopathologists examine stained tissue microscopically to assess CD45 protein expression and confirm blood-cell lineage.

CD45/LCA is often included as part of a broader immunophenotyping panel alongside markers such as CD3, CD20, CD5, CD10, CD30, CD43, and CD79a for precise lymphoma classification.

This test is especially valuable when routine histopathology findings are inconclusive or when distinguishing hematologic cancers from metastatic solid tumors is essential.

Accurate CD45/LCA expression analysis helps oncologists confirm diagnosis, determine prognosis, and guide personalized cancer treatment strategies.

Benefits of the Test

• Detects hematopoietic cell origin accurately
• Supports lymphoma and leukemia diagnosis
• Helps distinguish blood cancers from solid tumors
• Assists tumor classification
• Improves pathology diagnostic precision
• Supports personalized treatment planning

Why Doctors Recommend This Test

Doctors commonly recommend the CD45/LCA IHC Test when:

• Lymphoma is suspected
• Tissue involvement by leukemia is being evaluated
• Poorly differentiated tumor origin is unclear
• Differential diagnosis is required
• Routine biopsy findings are inconclusive
• Advanced hematologic tumor classification is needed
• Treatment planning depends on exact diagnosis
• Expert hematopathology confirmation is required

This test improves diagnostic confidence for accurate blood cancer management.

Preparation Before the Test

Preparation usually includes:

• Submission of FFPE tissue block or unstained slides
• Previous pathology reports
• Relevant clinical and imaging records
• Proper tissue labeling and packaging
• Laboratory authorization documentation

No fasting or direct patient preparation is required.

Normal Reporting Time

The normal reporting time for the CD45/LCA IHC Test is usually 4–7 working days, depending on staining complexity and interpretation requirements.

Who Should Take This Test?

This test is recommended for:

• Patients with suspected lymphoma or leukemia
• Individuals requiring hematologic tumor classification
• Patients with unclear tissue diagnosis
• Individuals under specialist hematology care
• Oncology patients requiring advanced pathology confirmation
• Patients needing expert immunohistochemistry evaluation

At Focus Diagnostics Hyderabad, advanced immunohistochemistry technology and expert hematopathology specialists ensure highly accurate CD45/LCA IHC reports for reliable diagnosis and personalized cancer treatment planning.